Novartis And Aventis Begin Merger Talks; Sanofi Considers Raising Bid
Executive Summary
Sanofi will continue to evaluate the market response to its tender offer for Aventis before deciding whether to sweeten its bid, CFO Marie-Helene Laimay said during a first quarter investor call April 22
You may also be interested in...
Novartis Misses Out On Another Merger, But Forces Sanofi To Pay More
Novartis will need to start over in its search for a merger partner after bowing out of the bidding process for Aventis
Sanofi-Aventis Deal Means More Leverage With Managed Care
Sanofi's $65 bil. merger with Aventis will offer the combined entity additional negotiating clout with large U.S. drug purchasers, Exec VP-Operations Hanspeter Spek said during an April 26 conference call
Sanofi Wins Aventis With $8 Bil. In Cash And Nominal Joint Control
Sanofi's winning bid for Aventis includes an additional $8 bil. in cash, nominal joint control of the merged company, and an acknowledgment of Aventis' Franco-German heritage